B BRAUN
SHARING EXPERTISE

Prontosan®
Askina® Calgitrol®

NOTHING'S GONNA STOP YOU NOW

PREVENTION AND TREATMENT OF WOUND INFECTION

Control and act

Acute and chronic wounds have a tendency to get infected and compromise the normal healing pathway, leading to a greater burden on health systems, long term disabilities and an overall reduction of a patient's quality of life.

WOUNDS

2,2 to 3 million wounds in EU [1]

Increased prevalence
The population prevalence of wounds in EU is 3-4/1000 people.

BIOFILM

Up to 90% chronic wounds with biofilm [2]

Up to 90% of chronic wounds contain biofilm with a role in wound infection.

INFECTION

50% of chronic wounds infected [3]

Half of chronic wounds are estimated to be infected.

1. J. Posnett, F. Gottrup, H. Lundgren and G. Saal: The resource Impact of wounds on health-care providers in Europe. J. Wound Care, Vol. 18, N°4, April 2009
2. Azevedo MM, Lisboa C, Cobrado L, Pina-Vaz C, Rodrigues A. Hard-to-heal wounds, biofilm and wound healing: an intricate interrelationship. Br J Nurs. 2020 Mar 12;29(5):S6-S13.
3.C. Dowsett: Adopting the two-week challenge in practice: making the case for silver dressings, Wounds UK, Vol. 10, N°2, 2014

SURGICAL SITE INFECTIONS

38% of all infections in surgical patients [4]

SSI are considered the most frequent complication in surgical patients.

LENGTH OF STAY

3-20 days increase in LOS (SSI) [5]

Surgical Site Infections increase the length of stay in hospitals by 3 to 20 days.

ESTIMATED COST

Up to **10 times** more cost for complications [6]

Costs of healing increase as the time to heal is greater and the incidence of compli-cations higher.

4.European Center for Disease Prevention and Control, Surveillance of surgical site infections in European hospitals –HAISSI protocol, version 1.02, 2012
5.World Health Organization: Hand Hygiene and the Surgical Patient Journey. http://www.who.int/gpsc/5may/EN_PSP_GPSC1_5May_2016/en/ (accessed Aug. 2016), 2016
6.G. Bennett, C. Dealeyand J. Posnett: The cost of pressure ulcers in the UK, Age and Aging, 33, 2004

Prontosan® – wound bed preparation taken seriously

Only a clean wound can heal

Prontosan® Wound Irrigation & Gel

INDICATIONS

Prontosan® Wound Irrigation Solution and **Prontosan® Wound Gel / Gel X** are indicated for cleansing and moistening of acute, chronic, infected skin wounds, 1st and 2nd degree burns (also 3rd degree for Prontosan® Wound Gel X).
They prevent the biofilm formation.

Prontosan® Wound Irrigation Solution is also ideal for moistening encrusted dressings, or bandages prior to removal and for instillation in combination with negative pressure wound therapy.

Prontosan® Gel and Gel X act as an effective barrier to reduce microbial penetration through the dressing and to decontaminate the wound bed between dressing changes.

ADVANTAGES

- Management and prevention of biofilm reformation [1] [2]
- Helps to prevent infections [3]
- Improved patient outcomes, including time to heal [4]
- Well-known substances with low allergenic potential [5]
- Can be used up to 8 weeks after first opening

Prontosan® Debridement Pad

INDICATIONS

Prontosan® Debridement Pad has been designed to support the Wound Bed Preparation with Prontosan® Wound Irrigation Solution. **Prontosan® Debridement Pad** frees the wound from coatings and dead cell residues (debris) and absorbs excess exudates and slough. Intact tissue is spared. **Prontosan® Debridement Pad** produces good results even with scaly and necrotic coatings, if they are subject to prior autolytic debridement.

ADVANTAGES

- Good cleansing and debridement due to microfiber technology
- Soft debridement, no tissue irritation
- Unique droplet shape to allow debridement of cavities and areas difficult to reach
- Blister packaging to allow safe and aseptic soaking of the pad prior to use
- Cleansing sheet composed of polyester and polypropylene microfiber supported by a backing layer made from polypropylene.

Prontosan® Debridement Pad
is intended for single use only

More information available at www.bbraun.com/prontosan

Askina® Calgitrol®

Treatment of local infection is essential for the healing process

INDICATIONS

Askina® Calgitrol® Ag, Askina® Calgitrol® THIN, Askina® Calgitrol® Paste are indicated for the management of exuding, partial to full thickness wounds, stage I-IV pressure sores, venous ulcers, second degree burns and donor sites.
Askina® Calgitrol® Paste is ideally suited for the management of tunnel wounds and small sinuses like in diabetic foot [7].

Askina® Calgitrol® Ag
Foam + silver alginate matrix

Askina® Calgitrol® THIN
Silver alginate matrix

ADVANTAGES

- The ionic silver alginate matrix gels in the presence of wound exudate and forms a moist wound environment conducive to natural healing conditions
- Tolerable [8]
- Easy to use, conformable [9]
- Helps prevent contamination from external bacteria

Askina® Calgitrol® Paste
Amorphous silver alginate matrix

PATENTED IONIC SILVER ALGINATE MATRIX – MODE OF ACTIONS:



APPLICATIONS

Askina® Calgitrol® Ag



In contact with wound exudate, the Calgitrol® ionic silver alginate matrix forms a soft gel.
To secure Askina® Calgitrol® Ag cover it with an appropriate secondary dressing[10]

Askina® Calgitrol® THIN

Askina® Calgitrol® THIN is also suitable for cavity wounds.
Cover it with an appropriate secondary dressing depending of the amount of exudate.[10]

Askina® Calgitrol® Paste



Askina® Calgitrol® Paste is conformable and allows an extremely close contact between the ionic silver alginate matrix and the wound bed, which is particularly valuable in difficult to manage wounds such as tunnels and sinuses.
Cover it with an appropriate secondary dressing depending of the amount of exudate[10]

For more information :

Naude L. The use of Prontosan® in combination of Askina® Calgitrol®: an independent case series. Wounds International, 2018 ; 9(1): 44-48. Available at http://www.woundsinternational.com (accessed 16.03.2018).

Ordering information

Prontosan®	Size	Pcs/Pack	Reference
Pod	40 ml	24	Individual article numbers by country
Bottle	350 ml	10	
Bottle	1,000 ml	10	
Wound Gel	30 ml	20	
Wound Gel X	50 g	20	
Wound Gel X	250 g	20	

Prontosan® Debridement Pad		Pcs/Pack	Reference
		3	3908456
		10	3908457

Askina® Calgitrol® Ag	Size	Pcs/Pack	Reference
	10 x 10 cm	10	6211010
	15 x 15 cm	10	6211510
	20 x 20 cm	10	6212010
Askina® Calgitrol® THIN			
	5 x 5 cm	10	6205510
	10 x 10 cm	10	6201010
	10 x 20 cm	10	6202110
	20 x 20 cm	10	6202010
	20 x 40 cm	3	6202403

Askina® Calgitrol® Paste	Size	Pcs/Pack	Reference
Tube	15 g	5	6241505
Tube	15 g	10	6241510
Tube	100 g	1	6241001

Askina® Carbosorb	Size	Pcs/Pack	Reference
	10 x 10 cm	10	9025006

Askina® Foam	Size	Pcs/Pack	Reference
	5 x 7 cm	10	7240710
	10 x 10 cm	10	7241010
	10 x 20 cm	10	7241210
	20 x 20 cm	5	7242005

Lit. References:

1. Efficacy of various wound irrigation solutions against biofilms. Seipp HM, Hofmann S, Hack A, Skowronsky A, Hauri A., ZfW 2005;4(5):160-163.
2. Davis SC, Harding A, Gil J, Parajon F, Valdes J, Solis M & Higa A "Effectiveness of a polyhexanide irrigation solution on methicillin-resistant Staphylococcus aureus biofilms in a porcine wound model" in International Wound Journal ISSN 1742-4801, 2017, 1-8, © 2017 Medicalhelplines.com Inc and John Wiley & Sons Ltd doi: 10.1111/iwj.12734.
3. Moore, M 0.1% Polyhexanide-Betaine Solution as an Adjuvant in a Case-Series of Chronic Wounds, Surg Technology International, 2016.
4. Bellingeri, A. et al. "Effect Of A Wound Cleansing Solution On Wound Bed Preparation And Inflammation In Chronic Wounds: A Single-Blind RCT". Journal of Wound Care 25.3 (2016): 160-168. Web.
5. Evaluation of the efficacy and tolerability of a solution containing propyl betaine and polihexanide. Romanelli M, Dini V, Barbanera S, Bertone MS. Skin Pharmacol Physiol 2010;23 (Suppl 1):41-44.
6. Instruction for use: Askina® Calgitrol® Ag, Askina® Calgitrol® THIN, Askina® Calgitrol® Paste.
7. Opasanon S, Magnette A, Meuleniere F, Harding K. Askina® Calgitrol® Made Easy. Wounds International 2012; 3(1). Available from www.woundsinternational.com
8. Trial C, Darbas H, Lavigne J-P, Sotto A, Simoneau G, Tillet Y, et al. Assessment of the antimicrobial effectiveness of a new silver alginate wound dressing: a RCT. J Wound Care. 2010 Jan;19(1):20–6.
9. Wounds International. Using Askina® Calgitrol® Paste for the treatment of diabetic foot infection: case studies. London: Wounds International 2013. Available from www.woundsinternational.com
10. Instruction for use: Askina@ Calgitrol@ Ag, Askina@ Calgitrol@ THIN, Askina@ Calgitrol@ Paste

Notes

Distributed by:
B. BRAUN MEDICAL | 26 Rue Armengaud | 92210 Saint-Cloud - France
Tel. 01 41 10 53 00 | Fax 01 41 10 53 99
B. BRAUN MEDICAL | SAS with a share capital of 31 000 000 € | RCS Nanterre 562050856
www.bbraun.com/wound-management

Manufactured by :
B. Braun Medical AG | Infection Control | Seesatz 17 | 6204 Sempach | Switzerland
B. Braun Hospicare Ltd. | Collooney | Co. Sligo | Ireland

ZJ01276 Version 4 / 2021-10